DE60231475D1 - Materialien und methoden zur behandlung von hepatitis c - Google Patents

Materialien und methoden zur behandlung von hepatitis c

Info

Publication number
DE60231475D1
DE60231475D1 DE60231475T DE60231475T DE60231475D1 DE 60231475 D1 DE60231475 D1 DE 60231475D1 DE 60231475 T DE60231475 T DE 60231475T DE 60231475 T DE60231475 T DE 60231475T DE 60231475 D1 DE60231475 D1 DE 60231475D1
Authority
DE
Germany
Prior art keywords
hepatitis
treatment
materials
methods
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231475T
Other languages
English (en)
Inventor
Katarina Drakenberg
Mats A Persson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecules of Man AB
Original Assignee
Molecules of Man AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecules of Man AB filed Critical Molecules of Man AB
Application granted granted Critical
Publication of DE60231475D1 publication Critical patent/DE60231475D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60231475T 2001-01-12 2002-01-14 Materialien und methoden zur behandlung von hepatitis c Expired - Lifetime DE60231475D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26088901P 2001-01-12 2001-01-12
PCT/SE2002/000044 WO2002060954A1 (en) 2001-01-12 2002-01-14 Materials and methods for treatment of hepatitis c

Publications (1)

Publication Number Publication Date
DE60231475D1 true DE60231475D1 (de) 2009-04-23

Family

ID=22991075

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231475T Expired - Lifetime DE60231475D1 (de) 2001-01-12 2002-01-14 Materialien und methoden zur behandlung von hepatitis c

Country Status (5)

Country Link
US (2) US7250166B2 (de)
EP (1) EP1355948B1 (de)
AT (1) ATE425187T1 (de)
DE (1) DE60231475D1 (de)
WO (1) WO2002060954A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250166B2 (en) * 2001-01-12 2007-07-31 Molecules Of Man Ab Human monoclonal antibodies that bind hepatitis C virus (HCV) E1
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2005030793A2 (en) 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
US7083180B2 (en) * 2004-09-29 2006-08-01 Maverick American Llc Adjustable bicycle seat assemblies and methods of use
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
NZ579706A (en) 2007-02-21 2012-03-30 Univ Massachusetts Human antibodues against hepatitis C virus (HCV) E2 protein and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
CN103261223B (zh) 2010-10-13 2017-03-29 詹森生物科技公司 人制瘤素m抗体及使用方法
WO2015006337A2 (en) * 2013-07-08 2015-01-15 Nanjingjinsirui Science & Technology Biology Corporation Compositions and methods for increasing protein half-life in a serum
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526636D1 (de) * 1994-07-29 2002-06-13 Innogenetics Nv Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung
US6538114B1 (en) 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US6747136B2 (en) * 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
EP0947525A1 (de) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitope in der viralen Hüllproteine und spezifische Antikörper gegen diese Epitope: Verwendung für die detektion von viralantigene im empfängergewebe
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
US20030180284A1 (en) 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US7250166B2 (en) * 2001-01-12 2007-07-31 Molecules Of Man Ab Human monoclonal antibodies that bind hepatitis C virus (HCV) E1

Also Published As

Publication number Publication date
EP1355948A1 (de) 2003-10-29
ATE425187T1 (de) 2009-03-15
US7250166B2 (en) 2007-07-31
EP1355948B1 (de) 2009-03-11
US20090162373A1 (en) 2009-06-25
WO2002060954A8 (en) 2004-06-03
US20040208887A1 (en) 2004-10-21
WO2002060954A1 (en) 2002-08-08
US7837996B2 (en) 2010-11-23

Similar Documents

Publication Publication Date Title
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
DE60119734D1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
NO20044897L (no) Hepatitt C virus inhibitorer
DE60229059D1 (de) Proteomimetische verbindungen und verfahren
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
ATE512976T1 (de) Hemmer des hepatitis-c-virus
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
ATE377657T1 (de) Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
EA201170353A1 (ru) Антитела против гепатита с и их применение
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE401912T1 (de) Methoden der zubereitung von immunglobulin und dessen verwendungen
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
DE602005027228D1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
ATE206456T1 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition